Sabra Healthcare REIT (NASDAQ:SBRA) Releases FY 2026 Earnings Guidance

Sabra Healthcare REIT (NASDAQ:SBRA) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 1.540-1.550 for the period, compared to the consensus EPS estimate of 1.520.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on SBRA shares. Citizens Jmp increased their price objective on Sabra Healthcare REIT from $23.00 to $25.00 and gave the company a “market outperform” rating in a research report on Wednesday, July 22nd. Barclays reduced their price objective on Sabra Healthcare REIT from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Tuesday, October 13th. UBS Group decreased their target price on Sabra Healthcare REIT from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Tuesday, October 13th. Truist Financial boosted their target price on Sabra Healthcare REIT from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, July 22nd. Finally, Mizuho set a $21.00 target price on Sabra Healthcare REIT in a report on Monday, August 31st. Seven research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, Sabra Healthcare REIT has a consensus rating of “Moderate Buy” and an average target price of $21.50.

Sabra Healthcare REIT Stock Down 0.1%

SBRA stock opened at $19.72 on Tuesday. Sabra Healthcare REIT has a 12-month low of $17.53 and a 12-month high of $22.77. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.95. The company has a market cap of $5.04 billion, a price-to-earnings ratio of 75.85, a PEG ratio of 1.73 and a beta of 0.63. The company has a 50 day moving average of $19.86 and a two-hundred day moving average of $19.96.

Sabra Healthcare REIT (NASDAQ:SBRA) last posted its quarterly earnings results on Monday, November 2nd. The real estate investment trust reported $0.11 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.05). Sabra Healthcare REIT had a net margin of 7.61% and a return on equity of 2.34%. The company had revenue of $249.57 million for the quarter, compared to analysts’ expectations of $236.64 million. During the same quarter in the prior year, the firm earned $0.38 earnings per share. The company’s revenue was up 31.4% on a year-over-year basis. On average, equities analysts anticipate that Sabra Healthcare REIT will post 1.52 earnings per share for the current fiscal year.

Insider Transactions at Sabra Healthcare REIT

In related news, CEO Richard Matros sold 200,000 shares of Sabra Healthcare REIT stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $20.83, for a total transaction of $4,166,000.00. Following the completion of the sale, the chief executive officer owned 1,657,686 shares of the company’s stock, valued at approximately $34,529,599.38. This trade represents a 10.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.09% of the company’s stock.

Sabra Healthcare REIT News Roundup

Here are the key news stories impacting Sabra Healthcare REIT this week:

• Positive Sentiment: Sabra reported third-quarter earnings of $0.41 per diluted share, exceeding the consensus estimate of $0.16 and rising from $0.38 in the year-ago quarter. Revenue increased 31.4% year over year to $249.6 million, ahead of the $236.6 million analyst estimate. Earnings Flash
• Positive Sentiment: Key REIT performance measures were solid: third-quarter FFO was $0.40 per share, normalized FFO was $0.39, AFFO was $0.45 and normalized AFFO was $0.41. FFO surpassed the $0.40 consensus estimate and increased from $0.38 a year earlier. Sabra Tops Q3 FFO and Revenue Estimates
• Positive Sentiment: Management raised 2026 EPS guidance to $1.54-$1.55, above the $1.52 consensus forecast. The higher outlook may support investor confidence in operating performance and cash-generation prospects. Sabra Reports Third Quarter 2026 Results and Updates Guidance
• Positive Sentiment: Sabra also declared its quarterly dividend, reinforcing the stock’s income appeal for REIT investors. Sabra Reports Results and Declares Dividend
• Neutral Sentiment: Despite the earnings beat and improved guidance, the shares were little changed, suggesting investors may have largely anticipated the strong results or remain focused on REIT-specific factors such as interest rates, leverage and healthcare-property risks.

Sabra Healthcare REIT Company Profile

Sabra Healthcare REIT, Inc is a self-managed real estate investment trust that owns and invests in healthcare-related real estate. The company focuses primarily on properties used for skilled nursing and transitional care, senior housing, behavioral health, specialty hospitals and other healthcare services.

Sabra leases properties to healthcare operators and also provides capital through loans, joint ventures and other real estate investments. Its portfolio is designed to support a range of care settings, including facilities serving seniors, patients requiring rehabilitation and individuals receiving behavioral healthcare.

Founded in 2010 and headquartered in Irvine, California, Sabra has expanded through acquisitions, development investments and strategic transactions, including its 2017 combination with Care Capital Properties.